Introduction

Method

Result

Discussion

(Reference)

:

14 1413160.415.4511

:14

4235.7135.7128.575042.867.14

: ;

[] 2008-200918~60129925 mg/d +150 mg/dF+In=495 mg/d +47.5 mg/dF+Mn=50FSFI24FSFI25.50.05)F+I(P

2008-200918~60129925 mg/d +150 mg/dF+In=495 mg/d +47.5 mg/dF+Mn=50FSFI24FSFI25.50.05)F+IP

1 EPCsPCIEPCs 4ST3PCI24 h EPCsEPCsCD133+/VEGFR-2+

2 PCI0.043%0.043%0.014%0.018%ST0.040%0.036%EPCs0.111%0.078% (P

1 PCIEPCs 1619ST1319PCI24 h EPCsEPCsCD133+/VEGFR-2+

2 EPCsPCI0.043%0.043%0.014%0.018%ST0.040%0.036%0.111%0.078%(P

GB8170-8746550 12.14912.116.16916.212.15012.212.25012.2

Index Medicus

2

1 . 2005. ,200634966-970.

2.//3 1993561-585

Majken K. Jensen, Eric B.Rimm, Kenneth J.Mukamal, et al. The T111I variant in the endothelial lipase gene and risk of coronary heart disease in three independent populations. Eur Heart J, 2009,30:1584-1589.Jensen MK, Rimm EB, Mukamal KJ, et al.The T111I variant in the endothelial lipase gene and risk of coronary heart disease in three independent populations. Eur Heart J, 2009,30:1584-1589.

12

http://www.cma.org.cn

bbbbbb

F5

bb

-- 6~8

20073075,1.217 20084186,1.375 20094186,1.39653002010C

*